2017
Trends in Omalizumab Utilization for Asthma: Evidence of Suboptimal Patient Selection
Jeffery MM, Shah ND, Karaca-Mandic P, Ross JS, Rank MA. Trends in Omalizumab Utilization for Asthma: Evidence of Suboptimal Patient Selection. The Journal Of Allergy And Clinical Immunology In Practice 2017, 6: 1568-1577.e4. PMID: 28958746, DOI: 10.1016/j.jaip.2017.07.034.Peer-Reviewed Original ResearchConceptsOmalizumab initiationAsthma controlICS-LABAPatient selectionLow adherenceBetter asthma controlCohort of nonusersSuboptimal patient selectionPoor asthma controlLow adherence ratesPatient-level characteristicsLarge US databaseMedicare Advantage beneficiariesAsthma biologicsExacerbation frequencyOmalizumab useIncident useComparison cohortICS/Medication adherenceAdherence ratesPrevalent usersAdministrative claimsAsthmaUtilization trends
2016
Impact of Hospitalization for Acute Myocardial Infarction on Adherence to Statins Among Older Adults
Kronish IM, Ross JS, Zhao H, Muntner P. Impact of Hospitalization for Acute Myocardial Infarction on Adherence to Statins Among Older Adults. Circulation Cardiovascular Quality And Outcomes 2016, 9: 364-371. PMID: 27220368, PMCID: PMC4956547, DOI: 10.1161/circoutcomes.115.002418.Peer-Reviewed Original ResearchMeSH KeywordsAdministrative Claims, HealthcareAgedAged, 80 and overDatabases, FactualDyslipidemiasFemaleHealth Knowledge, Attitudes, PracticeHospitalizationHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMedicareMedication AdherenceMyocardial InfarctionRisk AssessmentRisk FactorsTherapeuticsTime FactorsUnited StatesConceptsAcute myocardial infarctionImpact of hospitalizationAMI hospitalizationMyocardial infarctionProportion of patientsPatients adherentStatin adherentNonadherent patientsAdherent patientsMedicare patientsHospitalizationAdministrative claimsStatinsMedicare beneficiariesPatientsPneumoniaSubsequent adherenceOlder adultsInfarctionRandom sampleAdherenceAdherentYearsProportionCohortMaking Data Submitted to the Food and Drug Administration More Visible
Ross JS. Making Data Submitted to the Food and Drug Administration More Visible. JAMA Internal Medicine 2016, 176: 1-1. PMID: 26752009, DOI: 10.1001/jamainternmed.2015.6773.Commentaries, Editorials and Letters